KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway

Oncogene

Volumn 26, Issue 54, 2007, Pages 7560-7568

  Bauer, S ^a,d   Duensing, A ^b   Demetri, G D ^c   Fletcher, J A ^a,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Gastrointestinal neoplasm; KIT; Oncogenic signaling; PI3 K; Sarcoma

Indexed keywords

IMATINIB; JANUS KINASE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE C GAMMA; PROTEIN KINASE B; STEM CELL FACTOR;

ANALYTIC METHOD; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PRIORITY JOURNAL;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; GASTROINTESTINAL STROMAL TUMORS; HUMANS; KINETICS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; SIGNAL TRANSDUCTION;

MAMMALIA;

EID: 36749030022     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210558     Document Type: Article

References (29)

1. Antonescu CR, Besmer P, Guo T, Arkun K, Hom G, Koryotowski B et al. (2005). Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 11: 4182-4190.
2. Bauer S, Hartmann JT, de Wit M, Lang H, Grabellus F, Antoch G et al. (2005a). Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib. Int J Cancer 117: 316-325.
3. Bauer S, Hubert C, Heinrich MC, Cohen PS, Bertagnolli MM, Demetri GD et al. (2005b). KIT hyperactivation in imatinib-resistant GIST: implications for salvage therapies. Proc Am Soc Clin Oncol 23: a9034.
4. Bauer S, Yu LK, Demetri GD, Fletcher JA. (2006). Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res 66: 9153-9161.
5. Cammenga J, Horn S, Bergholz U, Sommer G, Besmer P, Fiedler W et al. (2005). Extracellular KIT receptor mutants, commonly found in core binding factor AML, are constitutively active and respond to imatinib mesylate. Blood 106: 3958-3961.
6. Carter TA, Wodicka LM, Shah NP, Velasco AM, Fabian MA, Treiber DK et al. (2005). Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci USA 102: 11011-11016.
7. Corless CL, McGreevey L, Haley A, Town A, Heinrich MC. (2002). KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 160: 1567-1572.
8. Debiec-Rychter M, Cools J, Dumez H, Sciot R, Stul M, Mentens N et al. (2005). Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 128: 270-279.
9. Dematteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. (2000). Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 231: 51-58.
10. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J et al. (2006). Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 14: 1329-1338.
11. Demetri GD, Von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ et al. (2002). Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347: 472-480.
12. Duensing A, Medeiros F, McConarty B, Joseph NE, Panigrahy D, Singer S et al. (2004). Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene 23: 3999-4006.
13. Fletcher JA, Corless CL, Dimitrijevic S, Von Mehren B, Eisenberg B, Joensuu H et al. (2003). Mechanisms of resistance to imatinib mesylate (IM) in advanced gastrointestinal stromal tumor (GIST). Proc Am Soc Clin Oncol 22: a3275.
14. Frank DA. (1999). STAT signaling in the pathogenesis and treatment of cancer. Mol Med 5: 432-456.
15. Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ et al. (2006). Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 24: 4764-4774.
16. Heinrich MC, Corless CL, Demetri GD, Blanke CD, Von Mehren M, Joensuu H et al. (2003). Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 21: 4342-4349.
17. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S et al. (1998). Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279: 577-580.
18. Linnekin D. (1999). Signaling pathways activated by c-Kit in hematopoietic cells. Int J Biochem Cell Biol 31: 1053-1074.
19. Mohi MG, Boulton C, Gu TL, Sternberg DW, Neuberg D, Griffin JD et al. (2004). Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. Proc Natl Acad Sci USA 101: 3130-3135.
20. Ning ZQ, Li J, McGuinness M, Arceci RJ. (2001). STAT3 activation is required for Asp(816) mutant c-Kit induced tumorigenicity. Oncogene 20: 4528-4536.
21. Rossi F, Ehlers I, Agosti V, Socci ND, Viale A, Sommer G et al. (2006). Oncogenic Kit signaling and therapeutic intervention in a mouse model of gastrointestinal stromal tumor. Proc Natl Acad Sci USA 103: 12843-12848.
22. Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R et al. (2001). KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 61: 8118-8121.
23. Sawka-Verhelle D, Tartare-Deckert S, Decaux JF, Girard J, Van Obberghen E. (2000). Stat 5B, activated by insulin in a Jak-independent fashion, plays a role in glucokinase gene transcription. Endocrinology 141: 1977-1988.
24. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. (2004). Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305: 399-401.
25. Shivakrupa R, Bernstein A, Watring N, Linnekin D. (2003). Phosphatidylinositol 3′-kinase is required for growth of mast cells expressing the kit catalytic domain mutant. Cancer Res 63: 4412-4419.
26. Tuveson DA, Willis NA, Jacks T, Griffin JD, Singer S, Fletcher CD et al. (2001). STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 20: 5054-5058.
27. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY et al. (2004). Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364: 1127-1134.
28. Wardelmann E, Merkelbach-Bruse S, Pauls K, Thomas N, Schildhaus HU, Heinicke T et al. (2006). Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate. Clin Cancer Res 12: 1743-1749.
29. Wardelmann E, Thomas N, Merkelbach-Bruse S, Pauls K, Speidel N, Buttner R et al. (2005). Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. Lancet Oncol 6: 249-251.